Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate

Victor M Karpyak, Joanna M Biernacka, J. R. Geske, G. D. Jenkins, Julie M Cunningham, J. Rüegg, O. Kononenko, A. A. Leontovich, O. A. Abulseoud, D. K. Hall-Flavin, L. L. Loukianova, T. D. Schneekloth, M. K. Skime, J. Frank, M. M. Nöthen, M. Rietschel, F. Kiefer, K. F. Mann, Richard M Weinshilboum, Mark A FryeDoo Sup Choi

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Acamprosate supports abstinence in some alcohol-dependent subjects, yet predictors of response are unknown. To identify response biomarkers, we investigated associations of abstinence length with polymorphisms in candidate genes in glycine and glutamate neurotransmission pathways and genes previously implicated in acamprosate response. Association analyses were conducted in the discovery sample of 225 alcohol-dependent subjects treated with acamprosate for 3 months in community-based treatment programs in the United States. Data from 110 alcohol-dependent males treated with acamprosate in the study PREDICT were used for replication of the top association findings. Statistical models were adjusted for relevant covariates, including recruitment site and baseline clinical variables associated with response. In the discovery sample, shorter abstinence was associated with increased intensity of alcohol craving and lower number of days between the last drink and initiation of acamprosate treatment. After adjustment for covariates, length of abstinence was associated with the GRIN2B rs2058878 (P=4.6 × 10(-5)). In the replication sample, shorter abstinence was associated with increased craving, increased depressive mood score and higher alcohol consumption. Association of abstinence length with GRIN2B rs2058878 was marginally significant (P=0.0675); as in the discovery sample, the minor A allele was associated with longer abstinence. Furthermore, rs2300272, which is in strong linkage disequilibrium with rs2058878, was also associated with abstinence length (P=0.049). This is the first report of a replicated association of genetic markers with the length of abstinence in acamprosate-treated alcoholics. Investigation of the underlying mechanisms of this association and its usefulness for individualized treatment selection should follow.

Original languageEnglish (US)
Pages (from-to)e462
JournalTranslational Psychiatry
Volume4
DOIs
StatePublished - 2014

Fingerprint

Genetic Markers
Alcohols
Linkage Disequilibrium
Statistical Models
Alcoholics
Synaptic Transmission
Alcohol Drinking
Glycine
Genes
acamprosate
Glutamic Acid
Therapeutics
Biomarkers
Alleles

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. / Karpyak, Victor M; Biernacka, Joanna M; Geske, J. R.; Jenkins, G. D.; Cunningham, Julie M; Rüegg, J.; Kononenko, O.; Leontovich, A. A.; Abulseoud, O. A.; Hall-Flavin, D. K.; Loukianova, L. L.; Schneekloth, T. D.; Skime, M. K.; Frank, J.; Nöthen, M. M.; Rietschel, M.; Kiefer, F.; Mann, K. F.; Weinshilboum, Richard M; Frye, Mark A; Choi, Doo Sup.

In: Translational Psychiatry, Vol. 4, 2014, p. e462.

Research output: Contribution to journalArticle

Karpyak, VM, Biernacka, JM, Geske, JR, Jenkins, GD, Cunningham, JM, Rüegg, J, Kononenko, O, Leontovich, AA, Abulseoud, OA, Hall-Flavin, DK, Loukianova, LL, Schneekloth, TD, Skime, MK, Frank, J, Nöthen, MM, Rietschel, M, Kiefer, F, Mann, KF, Weinshilboum, RM, Frye, MA & Choi, DS 2014, 'Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate', Translational Psychiatry, vol. 4, pp. e462. https://doi.org/10.1038/tp.2014.103
Karpyak, Victor M ; Biernacka, Joanna M ; Geske, J. R. ; Jenkins, G. D. ; Cunningham, Julie M ; Rüegg, J. ; Kononenko, O. ; Leontovich, A. A. ; Abulseoud, O. A. ; Hall-Flavin, D. K. ; Loukianova, L. L. ; Schneekloth, T. D. ; Skime, M. K. ; Frank, J. ; Nöthen, M. M. ; Rietschel, M. ; Kiefer, F. ; Mann, K. F. ; Weinshilboum, Richard M ; Frye, Mark A ; Choi, Doo Sup. / Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. In: Translational Psychiatry. 2014 ; Vol. 4. pp. e462.
@article{f29eef20a7f142b49f22d6b38fe8eaed,
title = "Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate",
abstract = "Acamprosate supports abstinence in some alcohol-dependent subjects, yet predictors of response are unknown. To identify response biomarkers, we investigated associations of abstinence length with polymorphisms in candidate genes in glycine and glutamate neurotransmission pathways and genes previously implicated in acamprosate response. Association analyses were conducted in the discovery sample of 225 alcohol-dependent subjects treated with acamprosate for 3 months in community-based treatment programs in the United States. Data from 110 alcohol-dependent males treated with acamprosate in the study PREDICT were used for replication of the top association findings. Statistical models were adjusted for relevant covariates, including recruitment site and baseline clinical variables associated with response. In the discovery sample, shorter abstinence was associated with increased intensity of alcohol craving and lower number of days between the last drink and initiation of acamprosate treatment. After adjustment for covariates, length of abstinence was associated with the GRIN2B rs2058878 (P=4.6 × 10(-5)). In the replication sample, shorter abstinence was associated with increased craving, increased depressive mood score and higher alcohol consumption. Association of abstinence length with GRIN2B rs2058878 was marginally significant (P=0.0675); as in the discovery sample, the minor A allele was associated with longer abstinence. Furthermore, rs2300272, which is in strong linkage disequilibrium with rs2058878, was also associated with abstinence length (P=0.049). This is the first report of a replicated association of genetic markers with the length of abstinence in acamprosate-treated alcoholics. Investigation of the underlying mechanisms of this association and its usefulness for individualized treatment selection should follow.",
author = "Karpyak, {Victor M} and Biernacka, {Joanna M} and Geske, {J. R.} and Jenkins, {G. D.} and Cunningham, {Julie M} and J. R{\"u}egg and O. Kononenko and Leontovich, {A. A.} and Abulseoud, {O. A.} and Hall-Flavin, {D. K.} and Loukianova, {L. L.} and Schneekloth, {T. D.} and Skime, {M. K.} and J. Frank and N{\"o}then, {M. M.} and M. Rietschel and F. Kiefer and Mann, {K. F.} and Weinshilboum, {Richard M} and Frye, {Mark A} and Choi, {Doo Sup}",
year = "2014",
doi = "10.1038/tp.2014.103",
language = "English (US)",
volume = "4",
pages = "e462",
journal = "Translational Psychiatry",
issn = "2158-3188",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate

AU - Karpyak, Victor M

AU - Biernacka, Joanna M

AU - Geske, J. R.

AU - Jenkins, G. D.

AU - Cunningham, Julie M

AU - Rüegg, J.

AU - Kononenko, O.

AU - Leontovich, A. A.

AU - Abulseoud, O. A.

AU - Hall-Flavin, D. K.

AU - Loukianova, L. L.

AU - Schneekloth, T. D.

AU - Skime, M. K.

AU - Frank, J.

AU - Nöthen, M. M.

AU - Rietschel, M.

AU - Kiefer, F.

AU - Mann, K. F.

AU - Weinshilboum, Richard M

AU - Frye, Mark A

AU - Choi, Doo Sup

PY - 2014

Y1 - 2014

N2 - Acamprosate supports abstinence in some alcohol-dependent subjects, yet predictors of response are unknown. To identify response biomarkers, we investigated associations of abstinence length with polymorphisms in candidate genes in glycine and glutamate neurotransmission pathways and genes previously implicated in acamprosate response. Association analyses were conducted in the discovery sample of 225 alcohol-dependent subjects treated with acamprosate for 3 months in community-based treatment programs in the United States. Data from 110 alcohol-dependent males treated with acamprosate in the study PREDICT were used for replication of the top association findings. Statistical models were adjusted for relevant covariates, including recruitment site and baseline clinical variables associated with response. In the discovery sample, shorter abstinence was associated with increased intensity of alcohol craving and lower number of days between the last drink and initiation of acamprosate treatment. After adjustment for covariates, length of abstinence was associated with the GRIN2B rs2058878 (P=4.6 × 10(-5)). In the replication sample, shorter abstinence was associated with increased craving, increased depressive mood score and higher alcohol consumption. Association of abstinence length with GRIN2B rs2058878 was marginally significant (P=0.0675); as in the discovery sample, the minor A allele was associated with longer abstinence. Furthermore, rs2300272, which is in strong linkage disequilibrium with rs2058878, was also associated with abstinence length (P=0.049). This is the first report of a replicated association of genetic markers with the length of abstinence in acamprosate-treated alcoholics. Investigation of the underlying mechanisms of this association and its usefulness for individualized treatment selection should follow.

AB - Acamprosate supports abstinence in some alcohol-dependent subjects, yet predictors of response are unknown. To identify response biomarkers, we investigated associations of abstinence length with polymorphisms in candidate genes in glycine and glutamate neurotransmission pathways and genes previously implicated in acamprosate response. Association analyses were conducted in the discovery sample of 225 alcohol-dependent subjects treated with acamprosate for 3 months in community-based treatment programs in the United States. Data from 110 alcohol-dependent males treated with acamprosate in the study PREDICT were used for replication of the top association findings. Statistical models were adjusted for relevant covariates, including recruitment site and baseline clinical variables associated with response. In the discovery sample, shorter abstinence was associated with increased intensity of alcohol craving and lower number of days between the last drink and initiation of acamprosate treatment. After adjustment for covariates, length of abstinence was associated with the GRIN2B rs2058878 (P=4.6 × 10(-5)). In the replication sample, shorter abstinence was associated with increased craving, increased depressive mood score and higher alcohol consumption. Association of abstinence length with GRIN2B rs2058878 was marginally significant (P=0.0675); as in the discovery sample, the minor A allele was associated with longer abstinence. Furthermore, rs2300272, which is in strong linkage disequilibrium with rs2058878, was also associated with abstinence length (P=0.049). This is the first report of a replicated association of genetic markers with the length of abstinence in acamprosate-treated alcoholics. Investigation of the underlying mechanisms of this association and its usefulness for individualized treatment selection should follow.

UR - http://www.scopus.com/inward/record.url?scp=84991464453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991464453&partnerID=8YFLogxK

U2 - 10.1038/tp.2014.103

DO - 10.1038/tp.2014.103

M3 - Article

C2 - 25290263

AN - SCOPUS:84991464453

VL - 4

SP - e462

JO - Translational Psychiatry

JF - Translational Psychiatry

SN - 2158-3188

ER -